The Oncoguard Liver test may provide an additional tool to aid in the diagnosis of indeterminate liver lesions in patients at risk for HCC whom do not meet radiologic criteria for HCC (LR 5) and whom do not have an elevated AFP . This real-world single center retrospective study demonstrates similar specificities and sensitivities to the previously reported case control validation studies. OGL is a clinically useful non-invasive blood test which may help avoid critical delay in diagnosis of HCC and also avoid additional and potential challenging biopsies of indeterminate lesions.
"This patient demonstrates benefits of early diagnosis; less invasive treatment options leading to cure of HCC. How to use the mt-HBT in post HCC cure needs further investigation, but this case demonstrates the benefit of the mt-HBT."